Other
Increase (Decrease) in Accounts Receivable
Alnylam Pharmaceuticals Increase (Decrease) in Accounts Receivable decreased by 72.4% to $110.42M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 1385.4%, from $7.43M to $110.42M. Over 3 years (FY 2021 to FY 2024), Increase (Decrease) in Accounts Receivable shows a downward trend with a -5.3% CAGR.
Analysis
StatementIncome Statement
SectionOther
CategoryLiquidity
SignalContext dependent
VolatilityModerate
First reportedQ1 2016
Last reportedQ1 2026Apr 30, 2026
How to read this metric
An increase often signals rising sales or slower collections, while a decrease suggests improved collection efficiency or declining sales volume.
Detailed definition
Measures the net change in amounts owed to the company by customers for goods or services delivered on credit. It reflec...
Peer comparison
A fundamental working capital metric used by all companies to assess cash conversion cycles.
Metric ID:
other_increase_decrease_in_accounts_receivableHistorical Data
19 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $35.31M | -$3.67M | $59.45M | -$39.70M | -$6.40M | $38.42M | $53.27M | -$19.15M | $2.97M | $107.99M | $0.00 | -$410.00K | -$9.64M | $37.09M | $59.51M | $7.43M | $136.91M | $399.86M | $110.42M |
| QoQ Change | — | -110.4% | >999% | -166.8% | +83.9% | +700.5% | +38.6% | -136.0% | +115.5% | >999% | -100.0% | — | <-999% | +484.8% | +60.4% | -87.5% | >999% | +192.1% | -72.4% |
| YoY Change | — | — | — | — | -118.1% | >999% | -10.4% | +51.8% | +146.4% | +181.1% | -100.0% | +97.9% | -424.6% | -65.7% | — | >999% | >999% | +978.0% | >999% |
Range-$39.70M – $399.86M
CAGR+28.8%
Avg YoY Growth+478.7%
Median YoY Growth+122.1%
Increase (Decrease) in Accounts Receivable at Other Companies
Frequently Asked Questions
- What is Alnylam Pharmaceuticals's increase (decrease) in accounts receivable?
- Alnylam Pharmaceuticals (ALNY) reported increase (decrease) in accounts receivable of $110.42M in Q1 2026.
- How has Alnylam Pharmaceuticals's increase (decrease) in accounts receivable changed year-over-year?
- Alnylam Pharmaceuticals's increase (decrease) in accounts receivable increased by 1385.4% year-over-year, from $7.43M to $110.42M.
- What is the long-term trend for Alnylam Pharmaceuticals's increase (decrease) in accounts receivable?
- Over 3 years (2021 to 2024), Alnylam Pharmaceuticals's increase (decrease) in accounts receivable has grown at a -5.3% compound annual growth rate (CAGR), from $101.80M to $86.55M.
- What does increase (decrease) in accounts receivable mean?
- The change in the amount of money customers owe the company for past purchases.